Stevens Capital Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-53,761
| Closed | -$5.13M | – | 238 |
|
|
2025
Q4 | $5.13M | Sell |
53,761
-18,535
| -26% | -$1.82M | 1.8% | 10 |
|
|
2025
Q3 | $7.06M | Buy |
72,296
+36,784
| +104% | +$3.81M | 0.94% | 25 |
|
|
2025
Q2 | $3.81M | Buy |
35,512
+28,929
| +439% | +$2.93M | 1.04% | 25 |
|
|
2025
Q1 | $664K | Sell |
6,583
-999
| -13% | -$101K | 0.16% | 95 |
|
|
2024
Q4 | $677K | Sell |
7,582
-6,263
| -45% | -$551K | 0.27% | 107 |
|
|
2024
Q3 | $1.16M | Buy |
+13,845
| New | +$1.09M | 0.17% | 68 |
|
|
2021
Q3 | – | Sell |
-12,693
| Closed | -$543K | – | 186 |
|
|
2021
Q2 | $543K | Buy |
12,693
+3,472
| +38% | +$146K | 0.16% | 102 |
|
|
2021
Q1 | $356K | Buy |
+9,221
| New | +$349K | 0.2% | 76 |
|
|
2019
Q4 | – | Sell |
-106,372
| Closed | -$4.33M | – | 612 |
|
|
2019
Q3 | $4.33M | Buy |
+106,372
| New | +$4.51M | 0.39% | 72 |
|
|
2018
Q3 | – | Sell |
-45,672
| Closed | -$1.49M | – | 738 |
|
|
2018
Q2 | $1.49M | Buy |
+45,672
| New | +$1.38M | 0.05% | 371 |
|
|
2018
Q1 | – | Sell |
-297,147
| Closed | -$7.37M | – | 756 |
|
|
2017
Q4 | $7.37M | Buy |
+297,147
| New | +$8.2M | 0.29% | 111 |
|
|
2017
Q3 | – | Sell |
-63,884
| Closed | -$1.77M | – | 857 |
|
|
2017
Q2 | $1.77M | Sell |
63,884
-584,826
| -90% | -$15.5M | 0.07% | 328 |
|
|
2017
Q1 | $16.1M | Buy |
648,710
+410,873
| +173% | +$9.99M | 0.61% | 27 |
|
|
2016
Q4 | $5.14M | Sell |
237,837
-749,602
| -76% | -$16.4M | 0.21% | 134 |
|
|
2016
Q3 | $23.5M | Buy |
987,439
+774,704
| +364% | +$18.5M | 0.98% | 11 |
|
|
2016
Q2 | $4.97M | Buy |
+212,735
| New | +$4.6M | 0.2% | 151 |
|
|
2016
Q1 | – | Sell |
-88,037
| Closed | -$1.62M | – | 901 |
|
|
2015
Q4 | $1.62M | Buy |
88,037
+60,370
| +218% | +$1.08M | 0.06% | 328 |
|
|
2015
Q3 | $454K | Sell |
27,667
-67,860
| -71% | -$1.16M | 0.02% | 562 |
|
|
2015
Q2 | $1.69M | Buy |
+95,527
| New | +$1.71M | 0.06% | 315 |
|
|
2015
Q1 | – | Sell |
-633,355
| Closed | -$8.39M | – | 997 |
|
|
2014
Q4 | $8.39M | Sell |
633,355
-79,820
| -11% | -$1.02M | 0.28% | 103 |
|
|
2014
Q3 | $8.42M | Buy |
713,175
+109,451
| +18% | +$1.38M | 0.25% | 123 |
|
|
2014
Q2 | $7.71M | Buy |
+603,724
| New | +$7.85M | 0.21% | 138 |
|
|
2014
Q1 | – | Sell |
-323,956
| Closed | -$3.89M | – | 1076 |
|
|
2013
Q4 | $3.89M | Buy |
+323,956
| New | +$3.83M | 0.12% | 202 |
|
Other funds holding BSX
VCM
VPM
Stevens Capital Management's BSX Position: Q1 2026 in Review
Stevens Capital Management sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 53,761 shares — an estimated $5.13M sold.
Stevens Capital Management first reported a position in BSX in Q4 2013 and held it in 23 quarters. The position peaked at $23.5M in Q3 2016. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Stevens Capital Management reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
- Stevens Capital Management sold 53,761 Boston Scientific shares in Q1 2026, an estimated $5.13M.
- Stevens Capital Management first reported a position in Boston Scientific in Q4 2013 and held it in 23 quarters.
- Stevens Capital Management's Boston Scientific position peaked at $23.5M in Q3 2016.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Stevens Capital Management's 13F filing for Q1 2026, filed 11 May 2026.